Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)

ObjectivesConvalescent plasma (CP) as a passive source of neutralizing antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. We investigated its effectiveness for the treatment of COVID-19. DesignOpen-label, parallel-arm, phase II, multicentre, randomized controlled trial. SettingThirty-nine public and private hospitals across India. ParticipantsHospitalized, moderately ill confirmed COVID-19 patients (PaO2/FiO2: 200-300 or respiratory rate > 24/min and SpO2 [≤] 93% on room air). InterventionParticipants were randomized to either control (best standard of care (BSC)) or intervention (CP + BSC) arm. Two doses of 200 mL CP was transfused 24 hours apart in the intervention arm. Main Outcome MeasureComposite of progression to severe disease (PaO2/FiO2< 100) or all-cause mortality at 28 days post-enrolment. ResultsBetween 22nd April to 14th July 2020, 464 participants were enrolled; 235 and 229 in intervention and control arm, respectively. Composite primary outcome was achieved in 44 (18.7%) participants in the intervention arm and 41 (17.9%) in the control arm [aOR: 1.09; 95% CI: 0.67, 1.77]. Mortality was documented in 34 (13.6%) and 31 (14.6%) participants in intervention and control arm, respectively [aOR) 1.06 95% CI: -0.61 to 1.83]. InterpretationCP was not associated with reduction in mortality or progression to severe COVID-19. This trial has high generalizability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A priori measurement of neutralizing antibody titres in donors and participants may further clarify the role of CP in management of COVID-19. Trial registrationThe trial was registered with Clinical Trial Registry of India (CTRI); CTRI/2020/04/024775.

A compact-sized surface EMG sensor for myoelectric hand prosthesis

Myoelectric prosthesis requires a sensor that can reliably capture surface electromyography (sEMG) signal from amputees for its controlled operation. The main problems with the presently available EMG devices are their extremely high cost, large response time, noise susceptibility, less amplitude sensitivity, and larger size. This paper proposes a compact and affordable EMG sensor for the prosthetic application. The sensor consists of an electrode interface, signal conditioning unit, and power supply unit all encased in a single package. The performance of dry electrodes employed in the skin interface was compared with the conventional Ag/AgCl electrodes, and the results were found satisfactory. The envelope detection technique in the sensor based on the tuned RC parameters enables the generation of smooth, faster, and repeatable EMG envelope irrespective of signal strength and subject variability. The output performance of the developed sensor was compared with commercial EMG sensor regarding signal-to-noise ratio, sensitivity, and response time. To perform this, EMG data with both devices were recorded for 10 subjects (3 amputees and 7 healthy subjects). The results showed 1.4 times greater SNR values and 45% higher sensitivity of the developed sensor than the commercial EMG sensor. Also, the proposed sensor was 57% faster than the commercial sensor in producing the output response. The sEMG sensor was further tested on amputees to control the operation of a self-designed 3D printed prosthetic hand. With proportional control scheme, the myoelectric hand setup was able to provide quicker and delicate grasping of objects as per the strength of the EMG signal.

Upregulation of Slc39a10 gene expression in response to thyroid hormones in intestine and kidney.

A novel zinc transporter has been purified and cloned from rat renal brush border membrane. This transporter was designated as Zip10 encoded by Slc39a10 gene and characterized as zinc importer. Present study documents the impact of thyroid hormones on the expression of Zip10 encoded by Slc39a10 gene in rat model of hypo and hyperthyroidism. Serum T(3) and T(4) levels were reduced significantly in hypothyroid rats whereas these levels were significantly elevated in hyperthyroid rats as compared to euthyroid rats thereby confirming the validity of the model. Kinetic studies revealed a significant increase in the initial and equilibrium uptake of Zn(++) in both intestinal and renal BBMV of hyperthyroid rats in comparison to hypothyroid and euthyroid rats. By RT-PCR, Slc39a10 mRNA expression was found to be significantly decreased in hypothyroid and increased in hyperthyroid as compared to euthyroid rats. These findings are in conformity with the immunofluorescence studies that revealed markedly higher fluorescence intensity at periphery of both intestinal and renal cells isolated from hyperthyroid rats as compared to hypothyroid and euthyroid rats. Higher expression of Zip10 protein in hyperthyroid group was also confirmed by western blot. These findings suggest that expression of zinc transporter protein Zip10 (Slc39a10) in intestine and kidney is positively regulated by thyroid hormones.

Alkalicyamelurates, M3[C6N7O3].xH2O, M = Li, Na, K, Rb, Cs: UV-luminescent and thermally very stable ionic tri-s-triazine derivatives.

Cyamelurates are salts of cyameluric acid, a derivative of tri-s-triazine (1,3,4,6,7,9-hexaazacyclo[3.3.3]azine or s-heptazine). These compounds are thermally very stable and possess interesting structural and optical properties. Only very few tri-s-triazine derivatives have been reported in the literature. The water-soluble alkali cyamelurates were extensively characterized using NMR, FTIR, Raman, UV, luminescence spectroscopy and elemental analysis. In addition, the single crystal X-ray structure analyses of the four hydrates of lithium, sodium, potassium and rubidium cyamelurates (Li(3)[C(6)N(7)O(3)].6H(2)O; Na(3)[C(6)N(7)O(3)].4.5H(2)O; K(3)[C(6)N(7)O(3)].3H(2)O; Rb(3)[C(6)N(7)O(3)].3H(2)O) are presented. Thermogravimetric analysis shows that the dehydrated salts start to decompose at temperatures above 500 degrees C. The thermal stability does not depend on the cations which is in contrast to the analogous s-triazine salts, i.e. the alkali cyanurates M(3)[C(3)N(3)O(3)]. The photoluminescence spectra indicate a very strong solid state UV-emission with maxima between 280 and 400 nm.

GaFPO(3)(C(6)H(5)): a new fluorinated gallium phenylphosphonate with a layered network.

Crystals of gallium fluorophenylphosphonate were synthesized hydrothermally at 453 K under autogenous pressure. The solid crystallizes in the monoclinic system and its structure is built up by the connection of zigzag chains of edge-sharing GaO(4)F(2) octahedra to phenylphosphonate groups. This results in the formation of a layered structure, in which the phenyl groups point upward and downward from the inorganic sheet. The Ga atoms occupy the special positions 4a (inversion center) and 4e (twofold axis).